Research Output per year
Fingerprint Fingerprint is based on mining the text of the experts' scientific documents to create an index of weighted terms, which defines the key subjects of each individual researcher.
- 20 Similar Profiles
Tuberculosis
Medicine & Life Sciences
rifapentine
Medicine & Life Sciences
Pyrazinamide
Medicine & Life Sciences
Rifampin
Medicine & Life Sciences
Mycobacterium tuberculosis
Medicine & Life Sciences
Multidrug-Resistant Tuberculosis
Medicine & Life Sciences
Pharmaceutical Preparations
Medicine & Life Sciences
Linezolid
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 1999 2019
High-dose rifamycins enable shorter oral treatment in a murine model of mycobacterium ulcerans disease
Omansen, T. F., Almeida, D., Converse, P. J., Li, S. Y., Lee, J., Stienstra, Y., van der Werf, T., Grosset, J. H. & Nuermberger, E., Feb 1 2019, In : Antimicrobial agents and chemotherapy. 63, 2, e01478-18.Research output: Contribution to journal › Article
rifapentine
Rifamycins
Mycobacterium ulcerans
Rifampin
Buruli Ulcer
A multi-antigenic MVA vaccine increases efficacy of combination chemotherapy against Mycobacterium tuberculosis
Leung-Theung-Long, S., Coupet, C. A., Gouanvic, M., Schmitt, D., Ray, A., Hoffmann, C., Schultz, H., Tyagi, S., Soni, H., Converse, P. J., Arias, L., Kleinpeter, P., Sansas, B., Mdluli, K., Vilaplana, C., Cardona, P. J., Nuermberger, E., Marchand, J. B., Silvestre, N. & Inchauspé, G., May 1 2018, In : PLoS One. 13, 5, e0196815.Research output: Contribution to journal › Article
Vaccinia
Chemotherapy
Vaccinium
Mycobacterium tuberculosis
Combination Drug Therapy
Impact of clofazimine dosing on treatment shortening of the first-line regimen in a mouse model of tuberculosis
Ammerman, N., Swanson, R. V., Bautista, E. M., Almeida, D. V., Saini, V., Omansen, T. F., Guo, H., Chang, Y. S., Li, S. Y., Tapley, A., Tasneen, R., Tyagi, S., Betoudji, F., Moodley, C., Ngcobo, B., Pillay, L., Bester, L. A., Singh, S. D., Chaisson, R. E., Nuermberger, E. & 1 others, Jul 1 2018, In : Antimicrobial Agents and Chemotherapy. 62, 7, e00636-18.Research output: Contribution to journal › Article
Clofazimine
Tuberculosis
Pharmaceutical Preparations
Therapeutics
Multidrug-Resistant Tuberculosis
Long-acting formulations for the treatment of latent tuberculous infection: Opportunities and challenges
Swindells, S., Siccardi, M., Barrett, S. E., Olsen, D. B., Grobler, J. A., Podany, A. T., Nuermberger, E., Kim, P., Barry, C. E., Owen, A., Hazuda, D. & Flexner, C. W., Feb 1 2018, In : International Journal of Tuberculosis and Lung Disease. 22, 2, p. 125-132 8 p.Research output: Contribution to journal › Review article
Tuberculosis
Infection
HIV
Drug Compounding
Virus Diseases
Multiparameter Responses to Tedizolid Monotherapy and Moxifloxacin Combination Therapy Models of Children With Intracellular Tuberculosis
Deshpande, D., Srivastava, S., Nuermberger, E., Koeuth, T., Martin, K. R., Cirrincione, K. N., Lee, P. S. & Gumbo, T., Nov 28 2018, In : Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 67, 3, p. S342-S348Research output: Contribution to journal › Article
Linezolid
Tuberculosis
Mitochondrial Genes
Stem Cells
Therapeutics